Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBIT (2023 - 2024)

Sagimet Biosciences has reported EBIT over the past 2 years, most recently at -$18.2 million for Q4 2024.

  • Quarterly results put EBIT at -$18.2 million for Q4 2024, down 92.21% from a year ago — trailing twelve months through Dec 2024 was -$54.5 million (down 77.14% YoY), and the annual figure for FY2025 was -$56.9 million, down 4.47%.
  • EBIT for Q4 2024 was -$18.2 million at Sagimet Biosciences, down from -$16.9 million in the prior quarter.
  • Over the last five years, EBIT for SGMT hit a ceiling of -$6.8 million in Q1 2023 and a floor of -$18.2 million in Q4 2024.